Search

Search Bar
24/12/2025 PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease
Gifre, L, Fusaro, M, Lloret, MJ, Massó, E, Peris, P, Nogués, X, Gelpi, R, Prior-Español, A, Ara, J, Cozzolino, M, Ureña-Torres, PA, Bover, J. PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease. Journal of Clinical Medicine. 2025; 15(1)DOI:10.3390/jcm15010133. PMID:41517382. IF:2.900(Q1/2D).
01/12/2025 Long-term efficacy of migalastat in females with Fabry disease
Kallish, S, Camporeale, A, Hopkin, RJ, Jovanovic, A, Nordbeck, P, Veleva-Rotse, BO, Krusinska, E, Torra, R. Long-term efficacy of migalastat in females with Fabry disease. JOURNAL OF MEDICAL GENETICS. 2025; 62(12)DOI:10.1136/jmg-2024-110596. PMID:40897525. IF:3.700(Q2/3D).
01/10/2025 Orthostatic blood pressure reduction is associated with renal organ damage in fit elderly patients with arterial hypertension
Ramos-Galí, A, de la Sierra, A, Oliveras, A, Armario, P, Fierro, NA, Arias, P, Vazquez, S, Camps, C, Castellanos, P, Calero, F, de la Llama, PF. Orthostatic blood pressure reduction is associated with renal organ damage in fit elderly patients with arterial hypertension. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1920. PMID:. IF:5.600(Q1/1D).
01/10/2025 Nephrology and primary care: integrated care program for chronic kidney disease
de la Llama, PF, Fierro, NA, Llauger, MA, Feijoo, MAV, Piera, EC, Benito, S, Ramírez, ERV, Perich, LG, Calero, F. Nephrology and primary care: integrated care program for chronic kidney disease. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2025; 40DOI:10.1093/ndt/gfaf116.1416. PMID:. IF:5.600(Q1/1D).
01/09/2025 MPOX IN PEOPLE WITH HIV AND PREP USERS DURING THE 2022 OUTBREAK, SPAIN
March-Yagüe, A, Toledo, D, Díaz, A, Godoy, P, Pérez-Martinez, O, Pericas, C, Sánchez-Migallón, A, Domínguez, A. MPOX IN PEOPLE WITH HIV AND PREP USERS DURING THE 2022 OUTBREAK, SPAIN. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/06/2025 Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid, T, Elbarougy, DE, Lavu, S, Buia, G, Senum, SR, Olinger, E, Yang, HN, Mcdonnell, SK, Bublitz, JT, Ma, J, Audrézet, MP, Madsen, CD, Schauer, RS, Baker, TA, Gregory, AV, Orr, SE, Barroso-Gil, M, Neatu, R, Joli, G, Dahl, NK, Kline, TL, Gillion, V, Dahan, K, Jouret, F, Perrone, RD, Steinman, TI, Peters, DJM, Gitomer, BY, Watnick, TJ, Coto, E, Chebib, FT, Hogan, MC, Olson, JE, Larson, NB, Ars, E, Halbritter, J, Demoulin, N, Torres, VE, Sayer, JA, Cornec-Le Gall, E, Harris, PC, Genomics England Res Consortium, UK Biobank, HALT PKD, DIPAK, TAME PKD, Genkyst Studies, Mayo Clinic Biobank, Regeneron Genetics Ctr. Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2025; 36(6)DOI:10.1681/ASN.0000000613. PMID:39899384. IF:9.400(Q1/1D).